Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.

@article{Magill2006TriazoleCA,
  title={Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy.},
  author={Shelley S. Magill and Christine A. Shields and Cynthia L Sears and Michael M Choti and William G. Merz},
  journal={Journal of clinical microbiology},
  year={2006},
  volume={44 2},
  pages={529-35}
}
Candida spp. are common causes of bloodstream infections among hospitalized patients. Fluconazole (FLC) remains a first-line therapy for candidemia; and voriconazole (VRC), an expanded-spectrum triazole, was recently approved for the treatment of candidemia in nonneutropenic patients. In vitro studies have suggested that VRC has potent activity against Candida spp. with reduced susceptibilities to FLC. We present a case report of invasive candidiasis and candidemia due to a Candida glabrata… CONTINUE READING
47 Citations
23 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…